Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

This study has been terminated.
(Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.)
Sponsor:
Collaborator:
Abbott
Information provided by:
Walter Reed Army Medical Center
ClinicalTrials.gov Identifier:
NCT00397657
First received: November 8, 2006
Last updated: June 16, 2009
Last verified: June 2009

November 8, 2006
June 16, 2009
November 2006
August 2009   (final data collection date for primary outcome measure)
The primary endpoint is the change in carotid intima-media thickness between groups after 14 months [ Time Frame: 14 months ] [ Designated as safety issue: No ]
The primary endpoint is the change in carotid intima-media thickness between groups after 14 months
Complete list of historical versions of study NCT00397657 on ClinicalTrials.gov Archive Site
  • The change in lipid values and lipid subfractions [ Time Frame: 14 months ] [ Designated as safety issue: No ]
  • A composite endpoint consisting of all major adverse cardiovascular events (coronary heart disease death, myocardial infarction, myocardial revascularization, admission to the hospital for an acute coronary syndrome) [ Time Frame: 14 months ] [ Designated as safety issue: Yes ]
  • Drug discontinuation due to adverse effects [ Time Frame: 14 months ] [ Designated as safety issue: Yes ]
  • Quality of life measured with the EQ-5D questionnaire- a generic questionnaire for describing and valuing subjects' health-related quality of life that has been studied in cardiovascular subjects [ Time Frame: 14 months ] [ Designated as safety issue: No ]
  • The change in lipid values and lipid subfractions
  • A composite endpoint consisting of all major adverse cardiovascular events (coronary heart disease death, myocardial infarction, myocardial revascularization, admission to the hospital for an acute coronary syndrome)
  • Drug discontinuation due to adverse effects
  • Quality of life measured with the EQ-5D questionnaire- a generic questionnaire for describing and valuing subjects' health-related quality of life that has been studied in cardiovascular subjects
Not Provided
Not Provided
 
Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)

Recent evidence on the use of statin therapy indicates the potential for ultra-low levels of low-density lipoprotein (LDL-C) to provide greater protection from recurrent coronary heart disease (CHD) events. Thus, in August 2005, the guidelines for the treatment of lipid disorders (NCEP ATPIII) were revised to indicate that an LDL-C treatment goal of 70 mg/dL (revised from 100 mg/dL) was optional for patients with known CHD. In these same guidelines, low levels of high-density lipoprotein (HDL-C) are also suggested but not specifically proscribed as a target of therapy. Recently the ARBITER 2 trial has provided the first evidence of the potential of raising HDL-C with extended release niacin when added to statin monotherapy. However, whether this approach would be superior to a strategy in which lower concentrations of LDL-C are targeted is unknown.

The purpose of ARBITER 6 - HALTS is to compare HDL and LDL-focused strategies of lipid treatments for their effects of atherosclerosis. This study is a prospective, randomized, open-label, blinded endpoint trial comparing treatment strategies of either HDL-raising therapies or LDL reduction for dyslipidemia on carotid atherosclerosis. Subjects with known atherosclerotic coronary or vascular disease or otherwise at high cardiovascular risk through the presence of a coronary risk equivalent who are currently being treated with a statin will be eligible. Subjects will be randomly assigned in an allocation-concealed fashion to open label treatment with either Ezetimibe 10 mg/d for additional LDL-lowering OR Extended-release niacin (1 gm/d, titrated to max tolerable dose up to 2 gm/d) for HDL improvement.

The effects of these 2 different strategies of intensified lipid management on atherosclerosis will be assessed by the change in the carotid intima-media thickness, a validated surrogate endpoint. The data will help guide clinicians on the potential benefits of these lipid treatment strategies.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Atherosclerosis
  • Drug: extended release niacin
    Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
  • Drug: ezetimibe
    Ezetimibe 10mg once daily
  • Active Comparator: Extended release niacin
    Interventions:
    • Drug: extended release niacin
    • Drug: ezetimibe
  • Active Comparator: Ezetimibe
    Intervention: Drug: ezetimibe

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
400
October 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female subjects, ≥ 30 years old with either known atherosclerotic coronary or vascular disease OR coronary risk equivalents defined as either:

    • diabetes mellitus,
    • multiple coronary risk factors with a Framingham Risk Score > 2% per year, or
    • an elevated coronary calcium score (> 400 for men, > 200 for women)
  • Currently being treated with a statin (Simvastatin 20 mg/d or its equivalent) as monotherapy for treatment of hyperlipidemia
  • Recent lipids (within the past 3 months without interval change in the statin regimen) showing both: LDL-C < 100 mg/dL and HDL-C < 50 mg/dL (men) or < 55 mg/dL (women)

Exclusion Criteria:

  • Current use of or known intolerance to niacin or ezetimibe
  • Known history of liver disease (cirrhosis, chronic hepatitis) or abnormal liver associated enzymes, > 3x the upper laboratory reference value
  • Enrollment in another drug or device research protocol
  • Females who are pregnant, expect to get pregnant during the course of the study, or are breastfeeding
Both
30 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00397657
06-12027
Not Provided
Allen J Taylor, MD, Medstar Research Institute and Washington Hospital Center, Washington DC
Walter Reed Army Medical Center
Abbott
Principal Investigator: Allen J Taylor, MD Medstar Research Institute and Washington Hospital Center, Washington DC.
Walter Reed Army Medical Center
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP